Table 2.

Multivariate analysis of the odds of abandonment

Characteristic	Odds ratio	95% CI	P value
HCProa	0.57	[0.40, 0.83]	0.004
Age (years)	1.01	[1.01, 1.02]	< 0.001
Male	1.00	[0.91, 1.09]	0.953
Household income
$0–$29,999	Ref	–	–
$30,000–$49,999	0.95	[0.79, 1.15]	0.597
$50,000–$74,999	0.92	[0.77, 1.10]	0.320
$75,000–$74,999	0.93	[0.78, 1.11]	0.431
> $100,000	0.97	[0.82, 1.14]	0.671
Unknown	1.02	[0.87, 1.20]	0.810
Expected patient copay
$0–$25	Ref	–	–
$26–$100	2.13	[1.92, 2.36]	< 0.001
$101–$500	2.80	[2.45, 3.19]	< 0.001
$501–$1000	5.98	[5.01, 7.14]	< 0.001
$1001–$2000	6.33	[5.04, 7.96]	< 0.001
> $2000	10.72	[9.16, 12.54]	< 0.001
Calendar year
2012	Ref	–	–
2013	1.08	[0.99, 1.19]	0.082
2014	0.58	[0.52, 0.65]	< 0.001
2015	0.23	[0.13, 0.41]	< 0.001
Primary plan
Commercial	Ref	–	–
Employer group	0.75	[0.57, 0.98]	0.036
Third party administrator	0.43	[0.19, 0.98]	0.044
Pharmacy benefit manager	0.68	[0.53, 0.87]	0.002
Cash	1.19	[0.90, 1.59]	0.232
Processors	0.96	[0.67, 1.36]	0.798
Worker’s compensation	0.00	[0.00, 99.9]	0.951
Unspecified or missing	1.29	[1.02, 1.63]	0.037
PSP enrollment	0.23	[0.20, 0.25]	< 0.001
Initial claim at a specialty pharmacy	1.13	[1.04, 1.23]	0.004
Charlson Comorbidity Index	0.98	[0.93, 1.04]	0.568
Indication
Rheumatoid arthritis	1.27	[1.12, 1.44]	< 0.001
Crohn disease	0.59	[0.50, 0.70]	< 0.001
Ulcerative colitis	0.90	[0.74, 1.08]	0.248
Psoriasis	1.02	[0.90, 1.15]	0.799
Psoriatic arthritis	0.95	[0.84, 1.06]	0.328
Ankylosing spondylitis	0.96	[0.79, 1.16]	0.654

Estimates were produced using a logistic regression with abandonment of the earliest adalimumab claim as the dependent variable

ADA adalimumab, CI confidence interval, HCPro HUMIRA Complete Pro, PSP patient support program, Ref reference

^aNon-HCPro cohort was the reference